Entropy Technologies’s TG Therapeutics TGTX Stock Holding History

Entropy Technologies’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$744K	Sell	13,537 -31,873	-70%	-$1.3M	0.03%	578
2026 Q1	$1.51M	Sell	45,410 -15,005	-25%	-$447K	0.07%	335
2025 Q4	$1.8M	Buy	60,415 +53,867	+823%	+$1.76M	0.1%	268
2025 Q3	$237K	Buy	+6,548	New	+$216K	0.02%	709
2025 Q2	–	Sell	-30,859	Closed	-$1.22M	–	1016
2025 Q1	$1.22M	Buy	30,859 +22,079	+251%	+$743K	0.12%	234
2024 Q4	$264K	Sell	8,780 -22,420	-72%	-$643K	0.03%	569
2024 Q3	$730K	Buy	+31,200	New	+$681K	0.08%	340
2024 Q2	–	Sell	-53,969	Closed	-$821K	–	930
2024 Q1	$821K	Buy	53,969 +25,033	+87%	+$399K	0.09%	329
2023 Q4	$494K	Buy	+28,936	New	+$336K	0.09%	346

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Entropy Technologies's TGTX Position: Q2 2026 in Review

Entropy Technologies reduced its TG Therapeutics (TGTX) stake by 70% in Q2 2026, selling an estimated $1.3M and leaving 13,537 shares worth $744K. The position accounts for 0.03% of the portfolio, ranked #578.

Entropy Technologies first reported a position in TGTX in Q4 2023 and has held it in 9 quarters since. The position peaked at $1.8M in Q4 2025. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Entropy Technologies held 13,537 shares of TG Therapeutics worth $744K as of Q2 2026.
Entropy Technologies sold 31,873 TG Therapeutics shares in Q2 2026, an estimated $1.3M.
TG Therapeutics made up 0.03% of Entropy Technologies's portfolio in Q2 2026, its #578 holding.
Entropy Technologies first reported a position in TG Therapeutics in Q4 2023 and has held it in 9 quarters since.
Entropy Technologies's TG Therapeutics position peaked at $1.8M in Q4 2025.
430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Entropy Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.